Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

RDY

Key Factors to Evaluate Before Investing in Dr. Reddy's Laboratories Ltd (RDY)

Dr. Reddy's Laboratories Ltd marked a 5.4% change today, compared to -0.0% for the S&P 500. Is it a good value at today's price of $15.54? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:

  • Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide.

  • Dr. Reddy's Laboratories Ltd belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of 22.94 and an average price to book (P/B) of 3.19

  • The company's P/B ratio is 0.04

  • Dr. Reddy's Laboratories Ltd has a trailing 12 month Price to Earnings (P/E) ratio of 19.7 based on its trailing 12 month price to earnings (EPS) of $0.79 per share

  • Its forward P/E ratio is 17.9, based on its forward earnings per share (EPS) of $0.87

  • Over the last four years, Dr. Reddy's Laboratories Ltd has averaged free cash flows of $391.33 Million, which on average grew 9.5%

  • RDY's gross profit margins have averaged 55.0 % over the last four years and during this time they had a growth rate of 1.8 % and a coefficient of variability of 6.26 %.

  • Dr. Reddy's Laboratories Ltd has moved 4.8% over the last year compared to 11.5% for the S&P 500 -- a difference of -6.7%

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS